靶向药物曲妥珠单抗联合化疗对人类表皮生长因子受体2阳性局部晚期乳腺癌患者临床疗效研究

目的: 观察曲妥珠单抗联合化疗对人类表皮生长因子受体2(HER-2)阳性的局部晚期乳腺癌(LABC)临床治疗结果。方法: 将228例HER-2阳性手术无法切除的晚期乳腺癌病例随机分到曲妥珠单抗辅助疗法+化疗组或单纯化疗组。其中115例接受曲妥珠单抗+化疗,113例单纯接受化疗,经过10个疗程治疗后,观察两组患者中临床和病理的完全缓解人数及符合手术要求的人数。结果: 数据显示与单纯化疗相比,曲妥珠单抗+化疗组病例对治疗的临床完全缓解病例(cCR)(化疗+曲妥珠单抗组89%,单纯化疗组77%)、病理学完全缓解(pCR)病例(两组分别为43%和23%)以及乳房和腋下淋巴结完全缓解(tpCR)病例(分别为39%和20%)比例更高,同时可以使更多的患者获得手术和保留乳房的机会。结论: 曲妥珠单抗联合化疗药物治疗HER-2过度表达的局部晚期乳腺癌均有较好的临床疗效,是治疗晚期乳癌并延长生存时间的一种新方法。

Clinical effect of trastuzumab combined chemotherapy in patients with HER-2 positive locally advanced breast cancer

AIM: To observe the efficacy of trastuzumab in treating patients with HER-2 positive locally advanced breast cancer (LABC). METHODS: 228 HER-2 positive patients with unresectable locally advanced breast cancer patients were randomly divided into 2 groups. 115 patients received trastuzumab plus chemotherapy, 113 cases received chemotherapy alone. After 10 courses of treatment, the number of clinical and pathology complete remission and potentially eligible for surgery patients were observed. RESULTS: Compared with chemotherapy group, trastuzumab plus chemotherapy group had more higher proportion in complete remission(cCR)(89% in trastuzumab plus chemotherapy group and 77% in chemotherapy group), pathological complete response(pCR)(43% and 23% respectively) and breast and axillary lymph node complete remission(tpCR)(respectively 39% and 20%). Trastuzumab plus chemotherapy group had more chance to surgery and breast conservation. CONCLUSION: Trastuzumab combined with chemotherapy is an effective schedule in the treatment of HER-2 positive locally advanced breast.